Thanks for your comments Bripoz . My problem is we compare...

Thanks for your comments Bripoz . My problem is we compare Cavatak with T-Vec which is a one-off treatment against one disease - melanoma which makes a single buy ( Amgen/Biovex ) easily understood .Yet VLA has so many more treatment possibilities in the pipeline with breast , prostate , head and neck , lung ,bladder ,and pancreatic cancers ,as well as multiple myeloma , mesothelioma , and glioma .And I think this makes a sale more complicated .If T-Vec is worth a billion for the treatment of one type of cancer, are these other cancer treatments also worth a billion each ? I find it difficult to accept that one pharma could take all this on solo .If they or a conglomerate did , would each cancer treatment attract a separate royalty as it came on stream ?
If Cavatak is as successful as we all hope it will be , I think this could translate into billions upon billions .